News

Latham Wins Dismissal of Securities Action Involving Liver Disease Drug Developer

The case involved a clinical trial of Akero's only product, a drug candidate aimed at treating a liver disease. It's the ...
TipRanks on MSN13h

Akero Therapeutics’ Phase 3 NASH Study: A Potential Game-Changer?

Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical study. Akero Therapeutics is conducting a Phase 3 study titled A Phase ...